HUBEI PROVINCE, China--(BUSINESS WIRE)--Benda Pharmaceutical, Inc. (“Benda” or the “Company”) (OTCBB: BPMA), a China-based pharmaceutical company producing traditional Chinese and conventional medicines, as well as Gendicine®, the world’s first commercialized gene therapy medicine for the treatment of cancer, announced today that it has entered into a financial advisory agreement with CRT Capital Group LLC (“CRT”) to assist the Company in evaluating its strategic and financial alternatives, including M&A, joint venture, divestiture, spin-off, financing or other capital market transactions.
